Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Mesalazine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Asacol 800mg MR tablets contain the active substance mesalazine (also known as 5aminosalicylic acid) which is an anti-inflammatory drug used in the treatment of:
e Asacol 800mg MR tablets Do not take the Asacol 800mg MR tablets if you:
Warnings and precautions Talk to your doctor before taking Asacol 800mg MR tablets if you have any medical conditions or illnesses. Tell your doctor if you have:
Kidney stones may develop with use of mesalazine. Kidney stones are hard lumps that can cause pain in your sides and blood in your urine. Take care to drink enough liquid during treatment with mesalazine. This can help prevent kidney stones from developing. Driving and using machines Asacol 800mg MR tablets are not expected to affect your ability to drive or operate machinery. Important information about some of the ingredients of Asacol 800mg MR tablets
Sodium (salt). This medicine contains less than 1 mmol (23 mg) sodium per dosage unit, i.e. is essentially "sodium-free".
Asacol 800mg MR tablets Always take Asacol 800mg MR tablets exactly as your doctor has told you. You should check with your doctor if you are not sure. The tablets should be swallowed whole with water. Do not break, crush or chew the tablet. You can take them at any time of the day, with or without meals. While taking this medicine, make sure you drink enough fluids to stay hydrated. This is especially important if you have been vomiting, having diarrhoea, have a high fever or heavy sweating. This will help avoid problems with your kidneys. Recommended dose:
If you forget to take Asacol 800mg MR tablets If you forget to take a dose at the required time, take it as soon as you remember and continue taking your tablets as before. DO NOT take two doses together. If it is almost time for your next dose, wait until then and carry on as before. If you have any further questions on the use of this product, ask your doctor or pharmacist. 4. Possible side effects Like all medicines, Asacol 800mg MR tablets can cause side effects, although not everybody gets them. A drug allergy is a reaction your body has to a medicine. Allergic reactions can happen after taking Asacol. Tell your doctor if you have any of these symptoms:
• • • • •
Lung disease (allergic reactions and diseases which can cause difficulty breathing, chest pain, and dry cough) Kidney stones and pain in your sides (see also Section 2). Increased pressure within your skull (idiopathic intracranial hypertension), symptoms of which could be strong or recurrent headache, disturbed vision, or ringing or buzzing in the ears. Serious illness with blistering of the skin. These blisters can lead to skin peeling and result in painful, raw areas. This condition can also affect your mouth, eyes and genitals. Issues tolerating mesalazine. This can make your existing condition worse, causing severe diarrhoea and abdominal pain.
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any
not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
ASACOL 800MG MR TABLETS Keep out of the sight and reach of children. Please keep the moisture absorbing pouch in the bottle. The pouch is not part of your medicine and is marked DO NOT EAT. Keep the bottle tightly closed. Do not use Asacol 800mg MR tablets after the expiry date which is stated on the pack after 'Exp'. The expiry date refers to the last day of that month. Medicines should not be disposed in wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer need. This will help protect the environment.
What Asacol 800mg MR tablets contain The active substance is mesalazine. Each tablet contains 800 mg of mesalazine.
What Asacol 800mg MR tablets look like and contents of the pack
Asacol 800mg MR tablets are red-brown, coated, and oblong shaped, marked with WC 800. They are packed in a plastic bottle with a child- resistant closure that contains cotton/silica gel moisture absorbing pouches. Asacol 800mg MR tablets are available in packs of 12, 36, 84 or 180 tablets (not all pack sizes may be marketed). Marketing Authorisation Holder AbbVie Ltd. Maidenhead SL6 4UB UK Tel: +44 (0) 1628 561 090 Manufacturer Forest Laboratories Ireland Limited Clonshaugh Business and Technology Park, Clonshaugh, Dublin 17, D17 E400, Ireland or Allergan Pharmaceuticals International Limited Clonshaugh Business & Technology Park, Dublin 17, D17 E400, Ireland Getting more advice about ulcerative colitis or Crohn's ileo-colitis In addition to advice and information available from your doctor and pharmacist, you may wish to contact Crohn's and Colitis UK for Colitis and Crohn's Disease which offers information, advice and local support groups. Crohn's and Colitis UK, 1 Bishops Square (Helios Court), Hatfield Business Park, Hatfield, AL10 9NE Telephone Information Line: 01727 830038 Monday-Friday: 9am-5pm (except English bank holidays) Crohn's and Colitis Support Line: 0300 222 5700 Monday-Friday: 9am-5pm (except English bank holidays) To listen to or request a copy of this leaflet in Braille, large print or audio, please contact the Marketing Authorisation Holder. Asacol® is a Trademark This leaflet was last revised in January 2025
Asacol 800mg MR Tablets comes as tablet containing 800mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Asacol 800mg MR Tablets is mesalazine.
Medicines with the same active substance, strength and form include: Octasa 800 mg modified-release tablets. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Asacol 800mg MR Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Ulcerative colitis: For the treatment of mild to moderate acute exacerbations. For the maintenance of remission.
Crohn's ileo-colitis: For the maintenance of remission.
Swallow whole with water. Do not break, crush or chew the tablets before swallowing.
ADULTS:
Mild acute exacerbations of ulcerative colitis: Three tablets (2.4g) a day in divided doses.
Moderate acute exacerbations of ulcerative colitis: Six tablets (4.8g) a day in divided doses.
Maintenance of remission of ulcerative colitis: Up to three tablets (2.4g) a day once daily or in divided doses.
Maintenance of remission of Crohn's ileocolitis: Up to three tablets (2.4g) a day in divided doses.
ELDERLY: The normal adult dosage may be used unless renal function is impaired (see section 4.4).
CHILDREN: Not recommended.
A history of sensitivity to salicylates or any of the ingredients; renal sensitivity to sulfasalazine. Confirmed severe renal impairment (GFR less than 20 ml/min). Severe hepatic impairment. Gastric or duodenal ulcer, haemorrhagic tendency.
Geriatric Use
Use in the elderly should be cautious and subject to patients having normal renal function.
Intolerance
Mesalazine inhibits the thiopurine methyl-transferase (TPMT) activity in vitro and may therefore impair the metabolism of azathioprine, thioguanine and 6-mercaptopurine. Standard haematological indices (including the white cell count) should be monitored repeatedly in patients taking azathioprine, especially at the beginning of such combination therapy, whether or not mesalazine is prescribed.
Mesalazine has been implicated in the production of an acute intolerance syndrome characterized by cramping, acute abdominal pain and bloody diarrhoea, sometimes fever, headache and a rash; in such cases prompt withdrawal is required. The patient's history of sulfasalazine intolerance, if any, should be re-evaluated. If a rechallenge is performed later in order to validate the hypersensitivity, it should be carried out under close supervision and only if clearly needed, giving consideration to reduced dosage. The possibility of increased absorption of mesalazine and concomitant renal tubular damage as noted in the preclinical studies must be kept in mind. Patients on mesalazine 1000 mg, especially those on concurrent oral products which contain or release mesalazine and those with pre-existing renal disease, should be carefully monitored with urinalysis, BUN and creatinine testing.
Renal disorders
Mesalazine may produce red-brown urine discoloration after contact with sodium hypochlorite bleach (e.g., in toilets cleaned with sodium hypochlorite contained in certain bleaches).
Mesalazine is excreted rapidly by the kidney, mainly as its metabolite, N-acetyl-5-aminosalicylic acid. In rats, large doses of mesalazine injected intravenously produce tubular and glomerular toxicity. Asacol should be used with extreme caution in patients with confirmed mild to moderate renal impairment (see section 4.3). Patients on mesalazine should have renal function monitored, (with serum creatinine levels measured) prior to treatment start. Renal function should then be monitored periodically during treatment, for example every 3 months for the first year, then every 6 months for the next 4 years and annually thereafter, based on individual patient history. Physicians should take into account risk factors such as prior and concomitant medications, duration and severity of disease and concurrent illnesses. Mesalazine-induced nephrotoxicity should be suspected in patients developing renal dysfunction during treatment. Treatment with mesalazine should be discontinued if renal function deteriorates. If dehydration develops, normal electrolyte and fluid balance should be restored as soon as possible.
Nephrolithiasis
Cases of nephrolithiasis have been reported with the use of mesalazine, including stones of 100% mesalazine content. It is recommended to ensure adequate fluid intake during treatment.
Hepatic Failure
There have been reports of hepatic failure in patients with pre-existing liver disease who have been administered mesalazine. Evaluate the risk and benefits of using mesalazine in patients with known liver impairment.
Blood Dyscrasias
Serious blood dyscrasias (some with fatal outcome) have been reported very rarely with mesalazine. Haematological investigations including a complete blood count may be performed prior to initiation and whilst on therapy according to the physician's judgement. Such tests should be done immediately if the patient develops unexplained bleeding, bruising, purpura, anaemia, fever or sore throat. Treatment should be stopped if there is suspicion or evidence of blood dyscrasia.
Severe cutaneous adverse reactions
Severe cutaneous adverse reactions (SCARs), including Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment.
Mesalazine should be discontinued, at the first appearance of signs and symptoms of severe skin reactions, such as skin rash, mucosal lesions, or any other sign of hypersensitivity.
Sensitivity/Hypersensitivity
Caution should be exercised when mesalazine (5-ASA) is initially used in patients known to be allergic to sulfasalazine. These patients should be instructed to discontinue therapy if signs of rash or fever become apparent. In case of an allergic reaction, appropriate measures (standard of care) should be taken.
Cardiac hypersensitivity reactions
Mesalazine-induced cardiac hypersensitivity reactions (myo- and pericarditis) have rarely been reported with mesalazine containing products. In case of previous mesalazine-induced cardiac hypersensitivity Asacol must not be reintroduced. Caution should be taken in patients with previous myo- or pericarditis of allergic background regardless of its origin.
Pulmonary disease
Patients with pulmonary disease, in particular asthma, should be very carefully monitored during treatment.
Idiopathic intracranial hypertension
Idiopathic intracranial hypertension (pseudotumor cerebri) has been reported in patients receiving mesalazine. Patients should be warned for signs and symptoms of idiopathic intracranial hypertension, including severe or recurrent headache, visual disturbances or tinnitus. If idiopathic intracranial hypertension occurs, discontinuation of mesalazine should be considered.
Excipients with known effect warnings
Lactose
With reference to the presence of lactose monohydrate in the formulation, patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Sodium content
This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, i.e. is essentially "sodium-free".
'Asacol' tablets should not be given with lactulose or similar preparations, which lower stool pH and may prevent release of mesalazine.
Concurrent use of other known nephrotoxic agents, such as NSAIDs and azathioprine, may increase the risk of renal reactions (see section 4.4).
Monitor patients taking nephrotoxic drugs for changes in renal function and mesalazine-related adverse reactions.
The hypoglycaemic effect of sulfonylureas may be enhanced when administered with aminosalicylates (oral antidiabetics may be displaced from the binding sites of plasma proteins). 5- ASA was reported to inhibit coumarin anticoagulants, resulting in thrombosis.
Concomitant treatment with mesalazine may increase the risk of myelosuppression in patients receiving azathioprine, thioguanine or 6-mercaptopurine. The concurrent use of mesalazine with azathioprine, thioguanine or 6-mercaptopurine may increase the risk for blood dyscrasia. If concomitant use of mesalazine and azathioprine, thioguanine or 6-mercaptopurine cannot be avoided, monitor blood tests, including complete blood cell counts and platelet counts.
Several reports of possible interference with measurements, by liquid chromatography, of urinary normetanephrine have been observed in patients exposed to sulfasalazine or its metabolite, mesalazine.
Pregnancy
Mesalazine is known to cross the placental barrier, but the limited data available on its use in pregnant women do not allow accurate assessment of possible adverse effects.
Mesalazine should therefore be used with caution during pregnancy and lactation when the potential benefit outweighs the possible hazards in the opinion of the physician.
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3).
Lactation
Low concentrations of mesalazine and higher concentrations of its N-acetyl metabolite have been detected in human milk. While the clinical significance of this has not been determined, caution should be exercised when mesalazine is administered to a nursing woman. Hypersensitivity reactions like diarrhoea cannot be excluded. If the infant develops diarrhoea breastfeeding should be discontinued.
There are no data available on the effects of mesalazine on ability to drive and use machines.
In Phase III clinical studies in patients with moderate active ulcerative colitis, treated for 6 weeks with either 2.4g/day or 4.8g/day, there was no difference in the adverse event profiles between doses. The events are presented in the table below:
Adverse Events Reported in ≥ 2% of Patients in Either Treatment Group
Adverse Event*
Asacol 800 mg (4.8 g/day)
N = 213 (%)
Mesalazine 400 mg (2.4 g/day)
N = 235 (%)
Headache
16 (7.5%)
14 (6.0%)
Abdominal pain
9 (4.2%)
12 (5.1%)
Diarrhoea
8 (3.8%)
9 (3.8%)
Nausea
8 (3.8%)
4 (1.7%)
Respiratory infection
7 (3.3%)
4 (1.7%)
Exacerbation of colitis
6 (2.8%)
6 (2.6%)
Dyspepsia
6 (2.8%)
5 (2.1%)
Vomiting
6 (2.8%)
2 (0.9%)
Flatulence
5 (2.3%)
7 (3.0%)
Rectal disorder
4 (1.9%)
6 (2.6%)
Flu syndrome
3 (1.4%)
8 (3.4%)
Rash
3 (1.4%)
5 (2.1%)
Increased cough
1 (0.5%)
9 (3.8%)
Sinusitis
1 (0.5%)
5 (2.1%)
Rhinitis
0 (0.0%)
7 (3.0%)
*Adverse events are listed by decreasing frequency as observed in the 4.8 g/day treatment group
Adverse events seen with oral mesalazine products are predominantly gastrointestinal, including nausea, vomiting, diarrhoea, and abdominal pain. Headache and arthralgia/myalgia have also been reported.
Undesirable effects reported from clinical studies and post marketing surveillance are listed below. Common, (≥1/100 to <1/10), uncommon (≥ 1/1,000 to <1/100), rare (≥ 1/10,000 to <1/1,000), very rare (< 1/10,000), frequency not known (cannot be estimated from the available data).
System organ class
Common
(≥ 1/100 to < 1/10)
Uncommon
(≥ 1/1,000 to <1/100)
Rare
(≥ 1/10,000 to < 1/1,000)
Very rare
(< 1/10,000)
Frequency not Known
Blood and lymphatic system disorders
leucopenia,
neutropenia,
agranulocytosis,
aplastic anaemia and thrombocytopenia*
Immune system disorders
hypersensitivity reactions*
Nervous system disorders
headache
peripheral neuropathy,
vertigo
Idiopathic intracranial hypertension*
Cardiac disorders
myocarditis,
pericarditis*
Respiratory thoracic and mediastinal disorders
bronchospasm,
eosinophilic pneumonia
interstitial pneumonitis
Pleurisy, allergic and fibrotic lung reactions
Gastrointestinal disorders
nausea,
vomiting,
diarrhoea,
abdominal pain
pancreatitis
exacerbation of the symptoms of colitis
Constipation
Hepato-biliary disorders
abnormalities of hepatic function (including hepatic failure) / abnormal liver function test, hepatitis
Skin and subcutaneous tissue disorders
alopecia, lupus erythematosus-like reactions, rash (including urticaria), bullous skin reactions
erythema multiforme
Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)*
Musculoskeletal connective tissue and bone disorders
arthralgia/ myalgia
Renal and urinary disorders
interstitial nephritis and nephrotic syndrome.
Renal failure.*
nephrolithiasis*
Reproductive system and breast disorders
oligospermia (reversible)
General disorders and administration site conditions:
Drug fever
mesalazine-induced acute intolerance syndrome*
* See Section 4.4 for further information
Severe cutaneous adverse reactions (SCARs), including Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment (see section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
There have been no documented reports of serious toxicity in human resulting from massive overdosing with mesalazine. Under ordinary circumstances, mesalazine absorption from the colon is limited. Mesalazine is not metabolized to salicylate. There is no specific antidote for mesalazine overdose and treatment is symptomatic and supportive. It may include intravenous infusion of appropriate electrolytes.
Ask anything about Asacol 800mg MR Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.